BioCentury
ARTICLE | Company News

Theravance sales and marketing update

August 19, 2013 7:00 AM UTC

Theravance relaunched Vibativ telavancin in the U.S. almost two years after distribution was placed on hold in November 2011 due to an ongoing investigation of a third-party manufacturer's production equipment and processes. The wholesale acquisition cost is $299 for a 750 mg vial. In June, FDA approved Hospira Inc. (NYSE:HSP, Lake Forest, Ill.) as the new third-party manufacturer of the antibiotic. The injectable lipoglycopeptide antibiotic is approved in the U.S. to treat hospital-acquired (nosocomial) and ventilator-associated pneumonia caused by Staphylococcus aureus when alternative treatments are not suitable and to treat complicated skin and skin structure infections (cSSSIs) caused by susceptible Gram-positive bacteria (see BioCentury, Jan. 16, 2012). ...